Empowering Corporate Development Teams for Successful Inorganic Growth
Amplify your inorganic growth strategies and minimize risk & uncertainty by leveraging Real-World Data & Evidence, AI, and GenAI-powered solutions
Your Strategic Roadblocks

Building a
High-Fidelity
Candidates Pipeline
Accelerate due diligence with sharper opportunity targeting

Reducing
Uncertainty
and Risk
Proactive success mapping
to cut risks and boost decisions

Ensuring
Post-Deal
Value Realization
Realize full value post-deal with transparency and responsive strategy
Our Solutions
We leverage cutting-edge Real-World Data and advanced AI methodologies to address critical strategic needs across your M&A deal lifecycle
Target Scouting & Screening
Rapidly uncover and profile high-quality deal opportunities
- AI-powered scoring for strategic fit
- Real-time IP, funding & milestone alerts
- Full Corporate & Candidates’ asset landscape profiling
Predictive Due Diligence
Anticipate risks for better-informed investment decisions
- Clinical, regulatory & market PoS modeling
- Virtual cohorts and synthetic control benchmarks
- Evidence planning tailored to value drivers
Clinical Trial Optimization & Rescue
Safeguard asset value through smarter, data-informed trial strategies
- Adaptive design using Bayesian & ML algorithms
- AI-based identification of high-response subgroups
- Virtual arms for better trial comparators
Post-Deal Value Maximization
Track asset performance and adjust in real time to capture synergies
- Deal KPIs monitored through custom dashboards
- Quantification of synergy realization
- Agile recommendations for strategic optimization
Your Benefits


Enhanced decision-making through reduced uncertainty

Accelerated target identification and validation

Data-driven risk mitigation

Improved visibility and adaptive strategic execution

Maximized return on inorganic investments
See our Solutions in Action
Oncology & Immunology
Optimizing Clinical Strategies through Integrated Evidence Generation Planning

Oncology & Immunology
Optimizing Clinical Strategies through Integrated Evidence Generation Planning
See how we clarified evidence needs and operationalized a robust clinical roadmap to optimize strategic decisions

Challenge
- Unclear regulatory and payer requirements
- Difficulty prioritizing indications and investments
- High uncertainty affecting success and asset value
- Fragmented, unaligned evidence activities

Our Solution
- Mapped disease landscape and stakeholder needs
- Defined a targeted product profile (TPP)
- Identified priority gaps and value drivers
- Aligned evidence generation with strategic goals
- Co-built an operational evidence plan

Results and Impact
Enabled significant enhancement of asset value, reduced uncertainty, and accelerated strategic decisions through a clarified, actionable evidence roadmap

Neurology
Rescuing Value from Failed Trials to enable Strategic Acquisitions
See how we helped identify undervalued clinical trial assets by extracting actionable insights from failed clinical studies, enabling targeted acquisition decisions

Challenge
- Phase III trial failed primary endpoint despite Phase II success
- Inconsistent results between phases hard to explain
- Lack of clarity on responsive patient subgroups
- Risk of missing value in an apparently failed asset

Our Solution
- Applied Q-Finder®, a supervised proprietary subgroup discovery algorithm, to explore Phase III data for responder signals
- Combined data insights with expert review and literature
Identified responder profiles with strong efficacy and safety
- Statistically validated hypotheses to define target subgroups

Results and Impact
Helped reveal clinically meaningful subpopulations, unlocking hidden asset value and enabling confident, value-driven acquisition decisions

Dermatology
Optimizing Asset Strategy using Synthetic Control Arms
See how we leveraged external comparators and Real-World Data-driven simulations to clarify asset effectiveness, supporting strategic investment decisions

Challenge
- No active comparator in early-phase trials
- Hard to assess relative efficacy or positioning
- Limited view of competitive landscape and value
- Uncertainty about valuation and regulatory strategy

Our Solution
- Aligned scope with client’s evidence goals
- Mapped external comparators via registry & SLR
- Built synthetic control models for comparisons
- Ensured HTA-readiness and strategic communication

Results and Impact
Clarified therapeutic positioning, reduced uncertainty, and strengthened valuation and negotiation power for informed deal-making

Target Identification
Accelerating Deal Prospecting through AI-Powered Target Screening
See how we accelerated strategic target identification by combining advanced AI-driven technology scouting and data-driven market assessments in an intuitive digital interface

Challenge
- Manual and fragmented scouting workflows
- Late detection of strategic opportunities
- Subjective and inconsistent target evaluation

Our Solution
- Built an AI-powered engine for real-time opportunity detection
- Developed a multi-criteria scoring system for target qualification
- Create a secure, collaborative platform tailored to internal needs
- Integrated continuous user feedback to refine recommendations

Results and Impact
Faster and more objective deal sourcing, reduced cycle times, and improved strategic alignment through automated prospecting

Whether you’re aiming to accelerate your prospecting pipeline, optimize target valuation, or maximize post-deal synergies, we’re here to help

Let’s Co-Design the
Future of Strategic
Deal-Making
Whether you’re aiming to accelerate your prospecting pipeline, optimize target valuation, or maximize post-deal synergies, we’re here to help